Guggenheim initiated coverage on shares of Merus (NASDAQ:MRUS) in a report published on Friday, Benzinga’s Daily Ratings Newsletter reports. The brokerage issued a buy rating and a $25.00 price target on the biotechnology company’s stock.
MRUS has been the topic of a number of other reports. Berenberg Bank assumed coverage on shares of Merus in a report on Wednesday, March 27th. They issued a buy rating and a $35.00 price objective on the stock. Citigroup cut their price target on shares of Merus from $18.00 to $16.00 and set a neutral rating on the stock in a research note on Thursday, March 21st. BidaskClub upgraded shares of Merus from a strong sell rating to a sell rating in a research note on Friday, March 1st. Wedbush cut their price target on shares of Merus from $34.00 to $25.00 and set an outperform rating on the stock in a research note on Friday, April 5th. Finally, ValuEngine raised shares of Merus from a sell rating to a hold rating in a research report on Wednesday, March 6th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average target price of $23.00.
Shares of MRUS stock opened at $14.72 on Friday. Merus has a 52 week low of $11.00 and a 52 week high of $26.74. The company has a market capitalization of $308.73 million, a price-to-earnings ratio of -8.00 and a beta of -0.06.
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II study for treating gastric, ovarian, endometrial, and non-small cell lung cancers.
Featured Story: Diversification For Individual Investors
Receive News & Ratings for Merus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus and related companies with MarketBeat.com's FREE daily email newsletter.